ASCO: For chemo's nausea, olanzapine beats metoclopramide

May 17, 2012
ASCO: for chemo's nausea, olanzapine beats metoclopramide

(HealthDay) -- For patients receiving highly emetogenic chemotherapy who experience breakthrough chemotherapy-induced nausea and vomiting, treatment with olanzapine (Zyprexa) is significantly better than treatment with metoclopramide, according to a phase III study released May 16 in advance of presentation at the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in Chicago.

Rudolph M. Navari, M.D., Ph.D., from the Indiana University School of Medicine South Bend, and colleagues conducted a randomized double-blind trial in chemotherapy-naive patients receiving highly emetogenic chemotherapy. Patients who developed breakthrough emesis or nausea, despite receiving guideline-recommended prophylactic treatment for chemotherapy-induced , were randomly allocated to receive (42 patients) or metoclopramide (38 patients) orally for three days. Patients were monitored for 72 hours after treatment.

During the 72-hour observation period, the researchers found that 71 percent of patients receiving olanzapine and 32 percent receiving metoclopramide had no emesis (P < 0.01). During the observation period, the proportion of patients without nausea was 67 percent of those treated with olanzapine versus 24 percent of those treated with (P < 0.01). The investigators noted no grade 3 or 4 toxicities.

"This study suggests that olanzapine will be very useful in these patients who feel very sick and sometimes come to the clinic, hospital, or emergency room. As a result, patients will feel better," Navari said in a statement.

Explore further: Chemo-induced nausea remains big problem, study says

More information: Abstract
More Information

Related Stories

Chemo-induced nausea remains big problem, study says

June 2, 2011

A large, phase III study of four commonly used drug regimens to treat chemotherapy-induced nausea concluded that while two regimens were better at managing patients’ queasiness, none were totally effective – prompting ...

Recommended for you

Combination therapy can prevent cytostatic resistance

November 26, 2015

Researchers at Karolinska Institutet have found a new way of preventing resistance to cytostatics used in the treatment of cancers such as medulloblastoma, the most common form of malignant brain tumour in children. The promising ...

Forecasting the path of breast cancer in a patient

November 23, 2015

USC researchers have developed a mathematical model to forecast metastatic breast cancer survival rates using techniques usually reserved for weather prediction, financial forecasting and surfing the Web.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.